Cell Counting Devices Market - Global Outlook & Forecast 2024-2029

318 pages

152 tables

113 charts

5 region

22 countries

67 company

4 segments

Purchase Options

$4200.00
$4999.00
$5999.00
$2000.00

Have a question?

Please get in touch with our team in case of any queries

+1-312-235-2040

THE GLOBAL CELL COUNTING DEVICES MARKET SIZE IS EXPECTED TO REACH USD 18.64 BILLION BY 2029 FROM USD 12.39 BILLION IN 2023, GROWING AT A CAGR OF 7.04% DURING THE FORECAST PERIOD.

The Cell Counting Devices Market Size, Share, & Trends Analysis Report By

  • Product: Consumables and Instruments
  • Applications: Research, Development, & Bioprocessing, Clinical Diagnostics, and Other Applications
  • End-Users: Pharma & Biotech Companies, Diagnostics Laboratories, Research Institutes & Labs, CDMOs & CROs, and Other End-users
  • Geography: North America, Europe, APAC, Latin America, and Middle East & Africa

Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2024–2029.

Customize this Report

This report includes market data points, ranging from trend
analyses to market estimates & forecasts that you can customize

CELL COUNTING DEVICES MARKET REPORT SCOPE

REPORT ATTRIBUTEDETAILS
Market Size (2029)USD 18.64 Billion
Market Size (2023)USD 12.39 Billion
CAGR (2023-2029)7.04%
HISTORIC YEAR2020-2022
BASE YEAR2023
FORECAST YEAR2024-2029
SEGMENTS BYProduct, Applications, End-Users, and Geography
GEOGRAPHIC ANALYSIS North America, Europe, APAC, Latin America, and Middle East & Africa
KEY PLAYERSAbbott, Bio-Rad Laboratories, Boule, Danaher, Diatron, HORIBA, Merck KGaA, PerkinElmer, Siemens Healthineers, Sysmex Corporation, and Thermo Fisher Scientific
Interested in this Report?

Download a Sample!

INDUSTRY OVERVIEW

The global cell counting devices market was valued at USD 12.39 billion in 2023 and is expected to reach USD 18.64 billion by 2029, growing at a CAGR of 7.04% during the forecast period. The market has witnessed significant development in the past few years. Cell counting devices are essential for clinical and pharma & biotech industries, from research & development to final product development and manufacturing processes. The continued development of cell counters, from traditional and manual to automated, the integration of advanced tools and technologies, and the growth of the cell counting devices market have shown promising development in the coming years. Also, automated cell counting devices are changing the market landscape by offering several advantages over traditional ones. As the pharma, biotech, and healthcare industries are growing rapidly, their investment and understanding of automated cell counters are rising rapidly, accelerating market development.

MARKET TRENDS & DRIVERS

Technology Advancements in Cell Counting Devices
Cell counting is essential for biologists who work with/on cells for cell culture. Manual cell counting has been the most popular method in the past few decades and is commonly used across life sciences sectors. However, the development from manual to automated cell counting devices, integration and adoption of innovative technologies such as flow cytometry and image-based cell counting systems, and integration of new modules and tools are revolutionizing the cell counting devices market landscape and are expected to deliver significant growth opportunities. The most recent advancement, the introduction of image-based cell counters, delivers the benefits of continuous development of image analysis algorithms and machine learning for more consistent and faster counting. Certainly, computer-based image analysis helps detect features easily missed by the human eye. All these developments emerge rapidly as the industry develops with automated cell counting devices. These advanced systems lighten traditional methods' changeability, providing faster throughputs and superior accuracy.

Increasing Application Areas for Cell Counting Devices
Cell counting is an essential operation in several fields and industries. It is fundamental for research biologists who work with cells. From cell culture- seeding cells at adequate densities, monitoring cell health and proliferation, and facilitating proper passaging to vital for in-vitro experiments. Cell counting has become essential in several industries, from disease diagnosis to drug development and production, and has gained significant attention in the past few years. In pharmaceutical, academic, and industrial sectors, major factors, such as stem cell research, regenerative medicines, and personalized medicines, are trending factors closely associated with cell culture and analysis, which deliver lucrative opportunities for cell counting. Most biological applications work on cells, such as blood work, cell culture, and microbiology, expand the growth of the cell counting devices market. Also, the growing research across stem cell research and regenerative medicines offers lucrative opportunities for cell counting devices. In stem cell research and regenerative medicine development, the requirement of consistent cell counts to achieve successful work in research activities and cell counting devices play an essential role. In recent years, the rising attention in stem cell research across industry and academic sectors is due to cells' potential to alleviate and cure many health conditions.

Growing Burden of Chronic Disorders
The cell counting devices market is gaining popularity in the healthcare industry to diagnose, treat, and monitor several health conditions. Hospitals and clinics widely use cell counting devices to measure and determine patient health. In clinical diagnosis, hematology analysis of body fluids delivers valuable information and indicates clinical health conditions. The full blood count is regularly/routinely performed in health settings to measure diagnosis in health settings, which involves cell counting in blood samples. Moreover, the growing burden of chronic diseases boosts the demand for cell-counting devices. Cell counting is the most important consideration for cancer, autoimmune diseases, and CVD diseases, as well as for diagnosis, monitoring, and effective treatment delivery. Conversely, automated cell counting devices are recognized as vital to eliminating the extra workforce cost burden and monitoring development and manufacturing processes in drug discovery for these health conditions.

SEGMENTATION INSIGHTS

INSIGHTS BY PRODUCT

INSIGHTS BY PRODUCT 
The global cell counting devices market by product is segmented into consumables and instruments. The consumables segment holds the dominating segmental market share in 2023. The consumables in the cell counting procedures include assay, reagent, accessories, software analysis algorithms, assay kits, microplates, and accessories such as beads, slides, plates, and others. A broad range of consumables are used with cell counters that help optimize instrument setup, sampling preparation, and quality control. The application rate of cell-counting consumables is comparatively higher than that of instruments. Consumables are used and discarded, which demand continued investment that drives significant market growth.  

The instrument segment includes spectrophotometers, flow cytometers, hematology analyzers, manual cell counters/hemocytometers, automated cell counters, and Coulter counters. Cell counting devices, including manual and automated ones, are considered instruments in the study report. The growth of the segment heavily relies on technological advancements in cell counters. The available automated cell counters offer more precision and reduce the work burden and human errors. The popularity of automated cell counters is accelerating segmental growth. Furthermore, automated cell counters offer higher throughput and become an alternative to other cell counter instruments; apart from that, the rising preference for flow cytometers, spectrophotometers, and Coulter counters positively influences segmental growth. The industry has many cell-counting devices, and they all work differently. The rising application areas for cell counters, from healthcare to breweries and dairy industries, have boosted the market share significantly. 

INSIGHTS BY APPLICATION
The global cell counting devices market by applications is segmented into research, development, & bioprocessing, clinical diagnostics, and other applications. The research, development, & bioprocessing segment holds the most significant share of the global market in 2023. The rapidly growing research, development, and bioprocessing activities across the life sciences are accelerating segmental growth. Furthermore, the growing application of cell counters in the medical field across disease diagnosis and associated activities are some of the leading factors propelling clinical diagnostics segmental growth.

INSIGHTS BY END-USERS
The global cell counting devices market by end-users is segmented into pharma & biotech companies, diagnostics laboratories, research institutes & labs, CDMOs & CROs, and other end-users. By end-users, the pharma & biotech companies accounted for most of the segmental market share in 2023. Pharma and biotech companies that are highly investing in the R&D of novel drugs and therapies widely perform research studies. Cell counting devices play a major role in developing cell and gene-based therapies, regenerative medicines, advanced biologics, vaccines, and others that require the study of various cells, where cell counters are most commonly used by pharma & biotech companies.

GEOGRAPHICAL ANALYSIS

North America dominated the global cell counting devices market share, accounting for a global share of over 36% in 2023. The region is dominating the global market with the rise in the aging population, prevalence of chronic diseases, increasing healthcare expenditure, need for advanced healthcare, presence of well-established players, and a major shift towards automation in cell counting devices. Most importantly, the presence of several manufacturers producing automated cell counting equipment with a wide range of products according to the margin of affordability contributes to the region’s highest share in the global market. Furthermore, in North America, the U.S. is a major market landscape that achieves the highest revenue growth for cell counting devices compared to other countries worldwide.

Europe holds a significant position in the global cell counting devices market in 2023. In Europe, a significant patient population with chronic diseases raises research and development activities across life sciences industries, delivering lucrative market growth opportunities. Furthermore, the growing research across cell and gene therapies, stem cells, and regenerative medicines drives the region's demand for automated cell counters. Also, APAC will likely be the fastest-growing region in the global cell counting devices market during the forecast period. This is mostly due to the growing aging population in need of diagnosis and treatment, the rise in prevalence of chronic diseases, demand for high-quality healthcare, growing healthcare infrastructure, and most importantly, the increasing number of healthcare centers such as hospitals, clinics, diagnostics centers, laboratories, and others.

VENDOR LANDSCAPE

The global cell counting devices market is exceptionally active, with several global, regional, and local players offering various cell counters. Also, the hematology analyzers used for cell analysis and counting significantly influence vendor competition. Several leading hematology analyzer companies compete with cell counting device manufacturing companies. The market is increasingly competitive, and vendors are highly focused on making partnerships and collaborations to maintain a competitive edge over other players. For instance, in 2022, Merck KGaA made a research collaboration and commercial license agreement with Mersana Therapeutics to discover novel antibody-drug conjugates.

Key players account for the major share of the global cell counting devices market. These key vendors include Abbott, Bio-Rad Laboratories, Boule, Danaher, Diatron, Merck KGaA, Horiba, Thermo Fisher Scientific, PerkinElmer, Siemens Healthineers, and Sysmex Corporation. Abbott offers high-quality hematology analyzers in the cell counting devices industry that meet a broad range of cell counting requirements. Abbott offers various medical diagnostics instruments, tests, automation, informatics, and solutions for multiple end-users. In 2018, Abbott strengthened its position in diagnostics by introducing Alinity, a separate platform for laboratory operations, tests, and services. Abbott has a complete portfolio of hematology solutions for cell count procedures, including automated analyzers, slide-maker strainers, reagents, calibrators, and controls for laboratories with diverse testing volumes. CELL-DYN Emerald 22 is the latest hematology analyzer introduced by Abbott.

Frequently Asked Questions

What is the growth rate of the global cell counting devices market?

The global cell counting devices market is expected to grow at a CAGR of 7.04% from 2023 to 2029.

How big is the cell counting devices market?

The global cell counting devices market size was valued at USD 12.39 billion in 2023 and is expected to reach USD 18.64 billion by 2029.

What are the significant trends in the cell counting devices industry?

Technology advancements in cell counting devices, increasing application areas for cell counting devices, and the rising focus on flow cytometry in cell counting are significant trends in the cell counting devices industry.

Which region dominates the global cell counting devices market share?

North America held the largest global cell counting devices market share, accounting for a share of over 36% in 2023.

Who are the key players in the global cell counting devices market?

Abbott, Bio-Rad Laboratories, Boule, Danaher, Diatron, HORIBA, Merck KGaA, PerkinElmer, Siemens Healthineers, Sysmex Corporation, and Thermo Fisher Scientific are the key players in the global cell counting devices market.

The global cell counting devices market size is expected to grow at a CAGR of approximately 7.04% from 2023 to 2029.

The following factors are likely to contribute to the growth of the global cell counting devices market during the forecast period:

  • Growing Burden of the Chronic Disorders
  • Rapid Shift from Manual to the Automated Cell Counting Devices
  • Continuously Increasing Research and Drug Discovery Activities

Base Year: 2023

Forecast Year: 2024-2029

The report considers the present scenario of the global cell counting devices market and its market dynamics for 2024−2029. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the industry. It also profiles and analyzes leading companies and several other prominent companies operating in the industry.

Key Company Profiles

  • Abbott
    • Business Overview
    • Product Offerings
    • Key Strategies
    • Key Strengths
    • Key Opportunities
  • Bio-Rad Laboratories
  • Boule
  • Danaher
  • Diatron
  • HORIBA
  • Merck KGaA
  • PerkinElmer
  • Siemens Healthineers
  • Sysmex Corporation
  • Thermo Fisher Scientific

Other Prominent Vendors

  • Advanced Instruments
    • Business Overview
    • Product Offerings
  • Agilent Technologies
  • Axion BioSystems
  • Aligned Genetics (Logos Biosystems)
  • Alphatec Scientific
  • Agappe Diagnostics
  • Analyticon Biotechnologies
  • Balio Diagnostics
  • B&E BIO-TECHNOLOGY
  • BioSystems Diagnostics
  • Bioway Biological Technology
  • BIOSYSY Scientific Devices GmbH
  • Benchmark Scientific
  • BD
  • Bruker Spatial Biology (NanoString Technologies, Inc.)
  • Bentley Instruments
  • ChemoMetec
  • Corning Incorporated
  • Curiosis Inc
  • Cytek Biosciences
  • Cole-Parmer Instrument Company
  • Cellular Technology Limited (Immunospot)
  • CLINDIAG SYSTEMS
  • CONTECH MEDICAL SYSTEMS
  • Convergent Technologies
  • CPC Diagnostics
  • DIAGON
  • Dirui
  • Drucker Diagnostics
  • DeNovix
  • EDAN Instruments
  • F. Hoffmann-La Roche
  • Genrui Biotech
  • High Technology
  • Hospitex International Ltd
  • LINEAR CHEMICALS
  • Maccura Biotechnology
  • Meril Life Sciences
  • Medsource Ozone Biomedicals
  • NIHON KOHDEN CORPORATION
  • Norma Instruments
  • NanoEntek
  • Paul Marienfeld GmbH & Co. KG
  • RWD Life Sciences Co., LTD.
  • Revvity
  • Sartorius AG
  • Shenzhen Mindray Bio-Medical Electronics
  • Shenzhen Landwind Industry
  • Prestige Diagnostics
  • SFRI
  • Shenzhen Dymind Biotechnology
  • Shenzhen Prokan Electronics
  • SPINREACT
  • Trivitron Healthcare
  • Tecan Trading Ag
  • Tip Biosystems

Segmentation by Product

  • Consumables
  • Instruments

Segmentation by Applications

  • Research, Development, & Bioprocessing
  • Clinical Diagnostics
  • Other Applications

Segmentation by End-Users

  • Pharma & Biotech Companies
  • Diagnostics Laboratories
  • Research Institutes & Labs
  • CDMOs & CROs
  • Other End-users

Segmentation by Geography

  • North America
    • The U.S.
    • Canada
  • Europe
    • Germany
    • France
    • The U.K.
    • Italy
    • Spain
    • Russia
    • Poland
  • APAC
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • South Africa
    • UAE

For more details, please reach us at enquiry@arizton.com

For more details, please reach us at enquiry@arizton.com

Select a license type that suits your business needs

Single User Licence

$4200.00
  • Report accessible by one user only
  • Free 10% or 3 days of customization
  • Free post-sale service assistance
  • Continuous support through email

5 User Licence

$4999.00
  • Report accessible by 5 users within the organization
  • Free 15% or 4.5 days of customization
  • Continuous support through email and telephone
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge

Corporate Licence

$5999.00
  • Free Datasheet worth $1500
  • Report accessible by the entire organization
  • Free 20% or 6 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Direct access to lead analysts
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge

Datasheet Licence

$2000.00
  • Report accessible by 1 user only
  • Free 15% or 32 hours of customization
  • Free post-sale service assistance
  • Direct access to lead analysts

Frequently Asked Questions

What is the growth rate of the global cell counting devices market?

The global cell counting devices market is expected to grow at a CAGR of 7.04% from 2023 to 2029.

How big is the cell counting devices market?

The global cell counting devices market size was valued at USD 12.39 billion in 2023 and is expected to reach USD 18.64 billion by 2029.

What are the significant trends in the cell counting devices industry?

Technology advancements in cell counting devices, increasing application areas for cell counting devices, and the rising focus on flow cytometry in cell counting are significant trends in the cell counting devices industry.

Which region dominates the global cell counting devices market share?

North America held the largest global cell counting devices market share, accounting for a share of over 36% in 2023.

Who are the key players in the global cell counting devices market?

Abbott, Bio-Rad Laboratories, Boule, Danaher, Diatron, HORIBA, Merck KGaA, PerkinElmer, Siemens Healthineers, Sysmex Corporation, and Thermo Fisher Scientific are the key players in the global cell counting devices market.